These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

181 related items for PubMed ID: 33866336

  • 1. Role of 68Ga-PSMA PET/CT parameters in treatment evaluation and survival prediction in prostate cancer patients compared with biochemical response assessment.
    Can C, Gündoğan C, Yildirim OA, Poyraz K, Güzel Y, Kömek H.
    Hell J Nucl Med; 2021; 24(1):25-35. PubMed ID: 33866336
    [Abstract] [Full Text] [Related]

  • 2. Efficacy of 68Ga-PSMA PET/CT-derived whole-body volumetric parameters in predicting response to second-generation androgen receptor axis-targeted therapy, and the prognosis in metastatic hormone-refractory prostate cancer patients.
    Oruç Z, Güzel Y, Ebinç S, Kömek H, Küçüköner M, Kaplan MA, Oruç İ, Urakçi Z, Işikdoğan A.
    Nucl Med Commun; 2021 Dec 01; 42(12):1336-1346. PubMed ID: 34366407
    [Abstract] [Full Text] [Related]

  • 3. Correlations between whole body volumetric parameters of 68Ga-PSMA PET/CT and biochemical-histopathological parameters in castration-naive and resistant prostate cancer patients.
    Yildirim ÖA, Gündoğan C, Can C, Poyraz K, Erdur E, Kömek H.
    Ann Nucl Med; 2021 May 01; 35(5):540-548. PubMed ID: 33586097
    [Abstract] [Full Text] [Related]

  • 4. More advantages in detecting bone and soft tissue metastases from prostate cancer using 18F-PSMA PET/CT.
    Pianou NK, Stavrou PZ, Vlontzou E, Rondogianni P, Exarhos DN, Datseris IE.
    Hell J Nucl Med; 2019 May 01; 22(1):6-9. PubMed ID: 30843003
    [Abstract] [Full Text] [Related]

  • 5. Clinical Factors That Influence Repeat 68Ga-PSMA-11 PET/CT Scan Positivity in Patients with Recurrent Prostate Cancer Under Observation After a Negative 68Ga-PSMA-11 PET/CT Scan: A Single-Center Retrospective Study.
    Thin P, Hotta M, Gafita A, Grogan T, Czernin J, Calais J, Sonni I.
    J Nucl Med; 2024 Oct 01; 65(10):1571-1576. PubMed ID: 39168522
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. A pictorial view on false positive findings of 68Ga-PSMA-11 PET/CT and their prognostic value in patients with prostate carcinoma after radical prostatectomy and undetectable PSA values.
    Dancheva Z, Chausheva S, Stoeva T, Dyankova M, Yordanova T, Chaushev B, Marinov R, Nikolov V, Abushev P, Todorov G, Dimitrova E, Klisarova A, Anakievski D.
    Hell J Nucl Med; 2024 Oct 01; 27(1):16-26. PubMed ID: 38629815
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Recurrent prostate cancer: combined role for MRI and PSMA-PET in 68Ga-PSMA-11 PET/MRI.
    Jannusch K, Bruckmann NM, Morawitz J, Boschheidgen M, Quick HH, Herrmann K, Fendler WP, Umutlu L, Stuschke M, Hadaschik B, Antoch G, Schimmöller L, Kirchner J.
    Eur Radiol; 2024 Jul 01; 34(7):4789-4800. PubMed ID: 38038758
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Can the Gleason score be predicted in patients with prostate cancer? A dynamic contrast-enhanced MRI, (68)Ga-PSMA PET/CT, PSA, and PSA-density comparison study.
    Akkaya H, Dilek O, Özdemir S, Taş ZA, Öztürk İS, Gülek B.
    Diagn Interv Radiol; 2023 Sep 05; 29(5):647-655. PubMed ID: 37395389
    [Abstract] [Full Text] [Related]

  • 15. Determination of whole-body tumour burden on [68Ga]PSMA-11 PET/CT for response assessment of [177Lu]PSMA-617 radioligand therapy: a retrospective analysis of serum PSA level and imaging derived parameters before and after two cycles of therapy.
    Michalski K, Mix M, Meyer PT, Ruf J.
    Nuklearmedizin; 2019 Dec 05; 58(6):443-450. PubMed ID: 31724145
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Comparison of discovery rates and prognostic utility of [68Ga]Ga-PSMA-11 PET/CT and circulating tumor DNA in prostate cancer-a cross-sectional study.
    Kluge K, Einspieler H, Haberl D, Spielvogel C, Amereller D, Egger G, Kramer G, Grubmüller B, Shariat S, Hacker M, Kenner L, Haug A.
    Eur J Nucl Med Mol Imaging; 2024 Jul 05; 51(9):2833-2842. PubMed ID: 38693454
    [Abstract] [Full Text] [Related]

  • 19. Impact of 68Ga-PSMA PET/CT on Survival and Management in Prostate Cancer.
    Algın E, Okudan B, Açıkgöz Y, Sayan H, Bal Ö, Seven B.
    Curr Med Imaging; 2024 Jul 05; 20():e15734056276494. PubMed ID: 38284703
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.